New York State Common Retirement Fund Cel Sci Corp Transaction History

New York State Common Retirement Fund

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$2.58 - $4.99 $60,611 - $117,230	-23,493 Reduced 98.9%	261 $1,000
Q1 2022 May 05, 2022	BUY	$3.93 - $7.7 $224 - $438	57 Added 0.24%	23,754 $93,000
Q4 2021 Feb 02, 2022	SELL	$7.1 - $12.82 $525 - $948	-74 Reduced 0.31%	23,697 $168,000
Q3 2021 Nov 02, 2021	SELL	$7.64 - $12.49 $55,099 - $90,077	-7,212 Reduced 23.28%	23,771 $261,000
Q2 2021 Aug 02, 2021	BUY	$8.68 - $27.49 $2,456 - $7,779	283 Added 0.92%	30,983 $269,000
Q2 2020 Aug 07, 2020	BUY	$9.75 - $17.6 $61,425 - $110,880	6,300 Added 25.82%	30,700 $458,000
Q1 2020 May 06, 2020	BUY	$7.54 - $17.05 $88,972 - $201,190	11,800 Added 93.65%	24,400 $282,000
Q4 2019 Feb 05, 2020	SELL	$6.71 - $9.55 $97,295 - $138,475	-14,500 Reduced 53.51%	12,600 $115,000
Q3 2019 Nov 07, 2019	BUY	$6.0 - $9.6 $600 - $960	100 Added 0.37%	27,100 $242,000
Q2 2019 Aug 09, 2019	BUY	$3.77 - $8.67 $101,790 - $234,090	27,000 New	27,000 $226,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.